| Sally Lohs, MD | |
|
12760 W North Ave Bldg A, Brookfield, WI 53005-4628 | |
| (262) 439-5500 | |
| (866) 439-5221 |
| Full Name | Sally Lohs |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 8 Years |
| Location | 12760 W North Ave Bldg A, Brookfield, Wisconsin |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396139671 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Milwaukee Psychiatric Physicians Chartered | 0840249751 | 6 |
News Archive
The United States Bone and Joint Decade (USBJD) today announces that as part of its 2009 Advocacy Day nearly 80 musculoskeletal patients and patient advocates from across the nation are participating in more than 175 Congressional visits. Patients and their advocates - physicians, family members and USBJD participating partners - are raising awareness of the huge burden that musculoskeletal conditions plays on the U.S. These conditions are some of the most costly, common, and disabling conditions to date.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
› Verified 9 days ago
| Entity Name | County Of Milwaukee |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942362066 PECOS PAC ID: 0446162887 Enrollment ID: O20031104000139 |
News Archive
The United States Bone and Joint Decade (USBJD) today announces that as part of its 2009 Advocacy Day nearly 80 musculoskeletal patients and patient advocates from across the nation are participating in more than 175 Congressional visits. Patients and their advocates - physicians, family members and USBJD participating partners - are raising awareness of the huge burden that musculoskeletal conditions plays on the U.S. These conditions are some of the most costly, common, and disabling conditions to date.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
› Verified 9 days ago
| Entity Name | Rogers Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053329581 PECOS PAC ID: 3476455809 Enrollment ID: O20040124000371 |
News Archive
The United States Bone and Joint Decade (USBJD) today announces that as part of its 2009 Advocacy Day nearly 80 musculoskeletal patients and patient advocates from across the nation are participating in more than 175 Congressional visits. Patients and their advocates - physicians, family members and USBJD participating partners - are raising awareness of the huge burden that musculoskeletal conditions plays on the U.S. These conditions are some of the most costly, common, and disabling conditions to date.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
› Verified 9 days ago
| Entity Name | Milwaukee Psychiatric Physicians Chartered |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588739155 PECOS PAC ID: 0840249751 Enrollment ID: O20070430000558 |
News Archive
The United States Bone and Joint Decade (USBJD) today announces that as part of its 2009 Advocacy Day nearly 80 musculoskeletal patients and patient advocates from across the nation are participating in more than 175 Congressional visits. Patients and their advocates - physicians, family members and USBJD participating partners - are raising awareness of the huge burden that musculoskeletal conditions plays on the U.S. These conditions are some of the most costly, common, and disabling conditions to date.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sally Lohs, MD 12760 W North Ave Bldg A, Brookfield, WI 53005-4628 Ph: (262) 439-5500 | Sally Lohs, MD 12760 W North Ave Bldg A, Brookfield, WI 53005-4628 Ph: (262) 439-5500 |
News Archive
The United States Bone and Joint Decade (USBJD) today announces that as part of its 2009 Advocacy Day nearly 80 musculoskeletal patients and patient advocates from across the nation are participating in more than 175 Congressional visits. Patients and their advocates - physicians, family members and USBJD participating partners - are raising awareness of the huge burden that musculoskeletal conditions plays on the U.S. These conditions are some of the most costly, common, and disabling conditions to date.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
A recent short-term spending plan that emerged from the House Appropriations Committee includes millions of dollars in cuts to federal health programs. Meanwhile, congressional efforts to reach agreement on a long-term spending plan may be getting more complicated.
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
› Verified 9 days ago
Mr. Chirag G. Shah, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 675 N Brookfield Rd Ste 205, Brookfield, WI 53045 Phone: 262-235-3311 | |
Makenzie Elizabeth Hatfield Kresch, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12760 W North Ave, Brookfield, WI 53005 Phone: 262-439-5500 | |
Mr. Gary K Schnell, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 12760 W North Ave, Building A, Brookfield, WI 53005 Phone: 262-439-5500 Fax: 866-439-5221 | |
Dr. Randall Joseph Zblewski, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 12760 W North Ave, Building A, Brookfield, WI 53005 Phone: 262-439-5500 Fax: 866-439-5221 | |
Dr. Marie Grace Ferber, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12760 W North Ave, Building A, Brookfield, WI 53005 Phone: 262-439-5500 Fax: 866-439-5221 | |
Corey Carr, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 13950 W Capitol Dr, 2nd Fl, Brookfield, WI 53005 Phone: 414-874-6288 |